Loading...
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
BACKGROUND: Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx...
Saved in:
Published in: | Onco Targets Ther |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6438145/ https://ncbi.nlm.nih.gov/pubmed/30988620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S194745 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|